← Eichor
Study identifier: NCT07087353 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy of Remote Monitoring in Patients Treated for Moderate to Severe Major Depressive Episodes

Condition: Mood Disorder (Depressive Episodes)  ·  Sponsor: Resilience

PhaseNA
Planned participants594
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Mood disorders like depression and bipolar disorder are widespread and cause serious psychological, cognitive, and social impairments, with a high burden on healthcare systems. Edra PRO is a digital medical device developed to support clinical decision-making and remotely monitor symptoms in psychiatric patients. The EC-102 randomized controlled trial will evaluate its impact compared to usual care on symptoms, quality of life, healthcare costs, comorbidities, and user adherence and satisfaction.

This description comes directly from the study's public registry record.

Talk to the study team

Emma Touré Cuq, PharmD  ·  +33646396617  ·  emma.tourecuq@resilience.care

Charles Ferté  ·  charles.ferte@resilience.care

Always discuss trial participation with your own doctor first.

Locations (6)

CHU BesançonBesançon, FranceRecruiting
CHU Grenoble AlpesGrenoble, FranceRecruiting
EPSM de VEndéeLa Roche-sur-Yon, FranceRecruiting
CHU de LilleLille, FranceRecruiting
Cabinet Corinne MARIELisieux, FranceRecruiting
CHU de ToulouseToulouse, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07087353